Evidence map›Paper›PMID 29059390›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2019

Cracking the Betel Nut: Cholinergic Activity of Areca Alkaloids and Related Compounds.

Nicole A Horenstein, Marta Quadri, Clare Stokes, Mohammed Shoaib, Roger L Papke

Open access · bronzeAbstract read
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Interventions for smokeless tobacco use cessation.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
  3. Review
  4. Targeting muscarinic receptors for treating schizophrenia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  5. Article
  6. Therapeutic Potential of Methanolic Extract ofJournal of pharmacopuncture · 2025
    Article
  7. Article
  8. In vitro hydrolysis of areca nut xenobiotics in human liver.Drug metabolism and pharmacokinetics · 2025
    Article
  9. Modulation of neural activity and gene expression by arecoline.Frontiers in integrative neuroscience · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. The Controversial Roles of Areca Nut: Medicine or Toxin?International journal of molecular sciences · 2023
    Review
  14. Article
  15. Plants with Anti-Addictive Potential.Advances in experimental medicine and biology · 2021
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Nicole A HorensteinDepartment of Chemistry, University of Florida, Gainesville, FL.
Marta QuadriDepartment of Chemistry, University of Florida, Gainesville, FL.
Clare StokesDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, FL.
Mohammed ShoaibInstitute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
Roger L PapkeDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, FL.
University of Florida · USNewcastle University · GB

Funding

Targeting of Alpha7 nAChR for therapeutic effectsR01GM057481 · NIGMS · UNIVERSITY OF FLORIDA · PI PAPKE, ROGER L · 2000 to 2023
$7.6M
NIGMS NIH HHS R01 GM057481
6 · The paper itself

Abstract

introductionThe use of betel quid is the most understudied major addiction in the world. The neuropsychological activity of betel quid has been attributed to alkaloids of Areca catechu. With the goal of developing novel addiction treatments, we evaluate the muscarinic and nicotinic activity of the four major Areca alkaloids: arecoline, arecaidine, guvacoline, and guvacine and four structurally related compounds.

methodsAcetylcholine receptors were expressed in Xenopus oocytes and studied with two-electrode voltage clamp.

resultsBoth arecoline- and guvacoline-activated muscarinic acetylcholine receptors (mAChR), while only arecoline produced significant activation of nicotinic AChR (nAChR). We characterized four additional arecoline-related compounds, seeking an analog that would retain selective activity for a α4* nAChR, with diminished effects on mAChR and not be a desensitizer of α7 nAChR. We show that this profile is largely met by isoarecolone. Three additional arecoline analogs were characterized. While the quaternary dimethyl analog had a broad range of activities, including activation of mAChR and muscle-type nAChR, the methyl analog only activated a range of α4* nAChR, albeit with low potency. The ethyl analog had no detectable cholinergic activity.

conclusionsEvidence indicates that α4* nAChR are at the root of nicotine addiction, and this may also be the case for betel addiction. Our characterization of isoarecolone and 1-(4-methylpiperazin-1-yl) ethanone as truly selective α4*nAChR selective partial agonists with low muscarinic activity may point toward a promising new direction for the development of drugs to treat both nicotine and betel addiction. IMPLICATIONS: Nearly 600 million people use Areca nut, often with tobacco. Two of the Areca alkaloids are muscarinic acetylcholine receptor agonists, and one, arecoline, is a partial agonist for the α4* nicotinic acetylcholine receptors (nAChR) associated with tobacco addiction. The profile of arecoline activity suggested its potential to be used as a scaffold for developing new tobacco cessation drugs if analogs can be identified that retain the same nicotinic receptor selectivity without muscarinic activity. We report that isoarecolone is a selective partial agonist for α4* nAChR with minimal muscarinic activity and 1-(4-methylpiperazin-1-yl) ethanone has similar nAChR selectivity and no detectable muscarinic action.

Indexed as

AlkaloidsAnimalsArecaArecolineBehavior, AddictiveCells, CulturedCholinergic AgentsHumansNicotinic AcidsOocytesReceptors, MuscarinicReceptors, NicotinicTobacco Use DisorderXenopus laevisAlkaloidsarecaidineArecolineCholinergic AgentsguvacineguvacolineisoarecoloneNicotinic AcidsReceptors, MuscarinicReceptors, Nicotinic

Identifiers

PMID29059390
PMCPMC6528145
OpenAlexW2762933329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.